These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35759355)

  • 1. Antiallergic Treatment of Bariatric Patients: Potentially Hampered Solubility/Dissolution and Bioavailability of Loratadine, but Not Desloratadine, Post-Bariatric Surgery.
    Porat D; Dukhno O; Vainer E; Cvijić S; Dahan A
    Mol Pharm; 2022 Aug; 19(8):2922-2936. PubMed ID: 35759355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective COX-2 inhibitors after bariatric surgery: Celecoxib, etoricoxib and etodolac post-bariatric solubility/dissolution and pharmacokinetics.
    Porat D; Dukhno O; Partook-Maccabi M; Vainer E; Cvijić S; Dahan A
    Int J Pharm; 2023 Oct; 645():123347. PubMed ID: 37633536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Complexity of Bariatric Patient's Pharmacotherapy: Sildenafil Biopharmaceutics and Pharmacokinetics before vs. after Gastric Sleeve/Bypass.
    Porat D; Dukhno O; Cvijić S; Dahan A
    Pharmaceutics; 2023 Dec; 15(12):. PubMed ID: 38140135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stomach pH before vs. after different bariatric surgery procedures: Clinical implications for drug delivery.
    Porat D; Vaynshtein J; Gibori R; Avramoff O; Shaked G; Dukhno O; Czeiger D; Sebbag G; Dahan A
    Eur J Pharm Biopharm; 2021 Mar; 160():152-157. PubMed ID: 33524534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lamotrigine therapy in patients after bariatric surgery: Potentially hampered solubility and dissolution.
    Porat D; Azran C; Mualem Y; Vainer E; Gibori R; Vaynshtein J; Dukhno O; Dahan A
    Int J Pharm; 2022 Jan; 612():121298. PubMed ID: 34793937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acid-base equilibria and solubility of loratadine and desloratadine in water and micellar media.
    Popović G; Cakar M; Agbaba D
    J Pharm Biomed Anal; 2009 Jan; 49(1):42-7. PubMed ID: 19013045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneously Predicting Pharmacokinetics of Loratadine and Desloratadine in Children Using a Whole-Body Physiologically Based Pharmacokinetic Model.
    Liu T; Mu R; Liu X
    J Clin Pharmacol; 2024 Aug; ():. PubMed ID: 39171895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation of loratadine nanocrystal tablets to improve the solubility and dissolution for enhanced oral bioavailability.
    Li J; Zhou Y; Aisha M; Wu J; Wang H; Huang F; Sun M
    J Pharm Pharmacol; 2021 Jun; 73(7):937-946. PubMed ID: 33963858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biopharmaceutical classification of desloratadine - not all drugs are classified the easy way.
    Berginc K; Sibinovska N; Žakelj S; Trontelj J; Legen I
    Acta Pharm; 2020 Jun; 70(2):131-144. PubMed ID: 31955139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac.
    Kambayashi A; Blume H; Dressman J
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1337-47. PubMed ID: 24056057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.
    Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS
    Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A mechanistic pharmacokinetic model to assess modified oral drug bioavailability post bariatric surgery in morbidly obese patients: interplay between CYP3A gut wall metabolism, permeability and dissolution.
    Darwich AS; Pade D; Ammori BJ; Jamei M; Ashcroft DM; Rostami-Hodjegan A
    J Pharm Pharmacol; 2012 Jul; 64(7):1008-24. PubMed ID: 22686346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous Determination of Loratadine and Its Metabolite Desloratadine in Beagle Plasma by LC-MS/MS and Application for Pharmacokinetics Study of Loratadine Tablets and Omeprazole‑Induced Drug-Drug Interaction.
    Zhang Y; Zhang J; Xu Q; Wang Y; Wu W; Wang W; Li X; Zhang T
    Drug Des Devel Ther; 2021; 15():5109-5122. PubMed ID: 34992347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Classification of loratadine based on the biopharmaceutics drug classification concept and possible in vitro-in vivo correlation.
    Khan MZ; Rausl D; Zanoski R; Zidar S; Mikulcić JH; Krizmanić L; Eskinja M; Mildner B; Knezević Z
    Biol Pharm Bull; 2004 Oct; 27(10):1630-5. PubMed ID: 15467209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling.
    Shono Y; Jantratid E; Janssen N; Kesisoglou F; Mao Y; Vertzoni M; Reppas C; Dressman JB
    Eur J Pharm Biopharm; 2009 Sep; 73(1):107-14. PubMed ID: 19465123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
    Tsume Y; Takeuchi S; Matsui K; Amidon GE; Amidon GL
    Eur J Pharm Sci; 2015 Aug; 76():203-12. PubMed ID: 25978875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dissolution evaluation in vitro and bioavailability in vivo of self-microemulsifying drug delivery systems for pH-sensitive drug loratadine.
    Li H; Tan Y; Yang L; Gao L; Wang T; Yang X; Quan D
    J Microencapsul; 2015; 32(2):175-80. PubMed ID: 25413271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Solubility enhancement of desloratadine by solid dispersion in poloxamers.
    Kolašinac N; Kachrimanis K; Homšek I; Grujić B; Ðurić Z; Ibrić S
    Int J Pharm; 2012 Oct; 436(1-2):161-70. PubMed ID: 22772487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo- and active-controlled trial.
    Crampton HJ
    Clin Ther; 2003 Jul; 25(7):1975-87. PubMed ID: 12946545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigating the use of liquisolid compacts technique to minimize the influence of pH variations on loratadine release.
    El-Hammadi M; Awad N
    AAPS PharmSciTech; 2012 Mar; 13(1):53-8. PubMed ID: 22101967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.